These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

438 related articles for article (PubMed ID: 29503156)

  • 21. The role of 123I-FP-CIT-SPECT in the differential diagnosis of Parkinson and tremor syndromes: a critical assessment of 125 cases.
    Sixel-Döring F; Liepe K; Mollenhauer B; Trautmann E; Trenkwalder C
    J Neurol; 2011 Dec; 258(12):2147-54. PubMed ID: 21547379
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum Ceruloplasmin and Striatal Dopamine Transporter Density in Parkinson Disease: Comparison With 123I-FP-CIT SPECT.
    Song YS; Kim JM; Kim KJ; Yun JY; Kim SE
    Clin Nucl Med; 2017 Sep; 42(9):675-679. PubMed ID: 28632695
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Speech difficulties in early de novo patients with Parkinson's disease.
    Polychronis S; Niccolini F; Pagano G; Yousaf T; Politis M
    Parkinsonism Relat Disord; 2019 Jul; 64():256-261. PubMed ID: 31078401
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Progression of tremor in early stages of Parkinson's disease: a clinical and neuroimaging study.
    Pasquini J; Ceravolo R; Qamhawi Z; Lee JY; Deuschl G; Brooks DJ; Bonuccelli U; Pavese N
    Brain; 2018 Mar; 141(3):811-821. PubMed ID: 29365117
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dynamic properties in functional connectivity changes and striatal dopamine deficiency in Parkinson's disease.
    Asendorf AL; Theis H; Tittgemeyer M; Timmermann L; Fink GR; Drzezga A; Eggers C; Ruppert-Junck MC; Pedrosa DJ; Hoenig MC; van Eimeren T
    Hum Brain Mapp; 2024 Jul; 45(10):e26776. PubMed ID: 38958131
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differences in nigro-striatal impairment in clinical variants of early Parkinson's disease: evidence from a FP-CIT SPECT study.
    Rossi C; Frosini D; Volterrani D; De Feo P; Unti E; Nicoletti V; Kiferle L; Bonuccelli U; Ceravolo R
    Eur J Neurol; 2010 Apr; 17(4):626-30. PubMed ID: 20050904
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Imaging of dopamine transporters with [123I]FP-CIT SPECT does not suggest a significant effect of age on the symptomatic threshold of disease in Parkinson's disease.
    Booij J; Bergmans P; Winogrodzka A; Speelman JD; Wolters EC
    Synapse; 2001 Feb; 39(2):101-8. PubMed ID: 11180497
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Validation of a standardized normalization template for statistical parametric mapping analysis of 123I-FP-CIT images.
    Kas A; Payoux P; Habert MO; Malek Z; Cointepas Y; El Fakhri G; Chaumet-Riffaud P; Itti E; Remy P
    J Nucl Med; 2007 Sep; 48(9):1459-67. PubMed ID: 17704252
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Measurement of [123I]FP-CIT binding to the dopamine transporter (DAT) in healthy mouse striatum using dedicated small animal SPECT imaging: feasibility, optimization and validation.
    Greco A; Zannetti A; Pappatà S; Albanese S; Coda AR; Ragucci M; Nardelli A; Brunetti A; Cuocolo A; Salvatore M
    Q J Nucl Med Mol Imaging; 2018 Mar; 62(1):112-117. PubMed ID: 26329495
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Imaging of dopamine transporters with iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson's disease.
    Booij J; Habraken JB; Bergmans P; Tissingh G; Winogrodzka A; Wolters EC; Janssen AG; Stoof JC; van Royen EA
    J Nucl Med; 1998 Nov; 39(11):1879-84. PubMed ID: 9829575
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serial dopamine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study.
    Iranzo A; Valldeoriola F; Lomeña F; Molinuevo JL; Serradell M; Salamero M; Cot A; Ros D; Pavía J; Santamaria J; Tolosa E
    Lancet Neurol; 2011 Sep; 10(9):797-805. PubMed ID: 21802993
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increased CSF DOPA Decarboxylase Correlates with Lower DaT-SPECT Binding: Analyses in Biopark and PPMI Cohorts.
    Khosousi S; Sturchio A; Appleton E; Paslawski W; Ta M; Nalls M; Singleton AB; Iwaki H; Svenningsson P
    Mov Disord; 2024 Oct; 39(10):1881-1885. PubMed ID: 38798037
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical correlates of raphe serotonergic dysfunction in early Parkinson's disease.
    Qamhawi Z; Towey D; Shah B; Pagano G; Seibyl J; Marek K; Borghammer P; Brooks DJ; Pavese N
    Brain; 2015 Oct; 138(Pt 10):2964-73. PubMed ID: 26209314
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical features and 123I-FP-CIT SPECT imaging in vascular parkinsonism and Parkinson's disease.
    Benítez-Rivero S; Marín-Oyaga VA; García-Solís D; Huertas-Fernández I; García-Gómez FJ; Jesús S; Cáceres MT; Carrillo F; Ortiz AM; Carballo M; Mir P
    J Neurol Neurosurg Psychiatry; 2013 Feb; 84(2):122-9. PubMed ID: 22906618
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential patterns of dopamine transporter loss in the basal ganglia of progressive supranuclear palsy and Parkinson's disease: analysis with [(123)I]IPT single photon emission computed tomography.
    Im JH; Chung SJ; Kim JS; Lee MC
    J Neurol Sci; 2006 May; 244(1-2):103-9. PubMed ID: 16473371
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET.
    Hansen AK; Knudsen K; Lillethorup TP; Landau AM; Parbo P; Fedorova T; Audrain H; Bender D; Østergaard K; Brooks DJ; Borghammer P
    Brain; 2016 Jul; 139(Pt 7):2039-49. PubMed ID: 27190023
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Application of texture analysis to DAT SPECT imaging: Relationship to clinical assessments.
    Rahmim A; Salimpour Y; Jain S; Blinder SA; Klyuzhin IS; Smith GS; Mari Z; Sossi V
    Neuroimage Clin; 2016; 12():e1-e9. PubMed ID: 27995072
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Distinct dopaminergic abnormalities in traumatic brain injury and Parkinson's disease.
    Jenkins PO; Roussakis AA; De Simoni S; Bourke N; Fleminger J; Cole J; Piccini P; Sharp D
    J Neurol Neurosurg Psychiatry; 2020 Jun; 91(6):631-637. PubMed ID: 32381639
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Direct comparison of FP-CIT SPECT and F-DOPA PET in patients with Parkinson's disease and healthy controls.
    Eshuis SA; Jager PL; Maguire RP; Jonkman S; Dierckx RA; Leenders KL
    Eur J Nucl Med Mol Imaging; 2009 Mar; 36(3):454-62. PubMed ID: 19037637
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 123I-FP-CIT SPECT [(123) I-2β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl) nortropane single photon emission computed tomography] Imaging in a p.A53T α-synuclein Parkinson's disease cohort versus Parkinson's disease.
    Koros C; Simitsi A; Prentakis A; Beratis I; Papadimitriou D; Kontaxopoulou D; Fragkiadaki S; Papagiannakis N; Seibyl J; Marek K; Papageorgiou SG; Trapali XG; Stamelou M; Stefanis L
    Mov Disord; 2018 Nov; 33(11):1734-1739. PubMed ID: 30288781
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.